enVVeno Medical Corp (NVNO)

Import this data to Google Sheets with:

=jivedata("NVNO","financials")

Full statements spill as a table. For one cell: =jivedata("NVNO","Revenue") or =jivedata("NVNO","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

enVVeno Medical Corp

NVNO • CIK 0001661053

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Research and Development Expense	$13,583	$12,249	$9,981	$8,720
Selling, General and Administrative Expense	$11,655	$11,577	$10,918	$8,034
Operating Income (Loss)	$-25,238	$-23,826	$-20,899	$-16,754
Net Income (Loss) Attributable to Parent	$-23,516	$-21,819	$-19,472	$-15,724
Weighted Average Number of Shares Outstanding, Basic	12,301,000	17,142,000	589,000	-19,097,000
Realized Investment Gains (Losses)	$1,074	$1,640	$1,126	$908
Unrealized Gain (Loss) on Investments	$468	$-22	$-391	$-183
Interest Income, Other	$180	$389	$692	$309
Nonoperating Income (Expense)	$1,722	$2,007	$1,427	$1,030

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$3,620	$1,754	$3,065	$2,841
Short-term Investments	$42,792	$41,399	$25,147	$18,645
Property, Plant and Equipment, Net	$334	$182	$51	$78
Prepaid Expense and Other Assets, Current	$511	$581	$614	$596
Operating Lease, Right-of-Use Asset	$1,347	$1,007	$654	$469
Assets, Current	$46,923	$43,734	$28,826	$22,082
Assets	$48,635	$44,954	$29,562	$22,660
Operating Lease, Liability, Noncurrent	$1,064	$700	$310	$103
Liabilities	$2,435	$2,795	$2,432	$1,990
Accounts Payable and Other Accrued Liabilities, Current	—	—	$1,732	$1,485
Operating Lease, Liability, Current	$338	$364	$390	$402
Liabilities, Current	$1,371	$2,095	$2,122	$1,887
Additional Paid in Capital	$176,236	$194,014	$198,457	$199,446
Retained Earnings (Accumulated Deficit)	$-130,036	$-151,855	$-171,327	$-178,776
Stockholders' Equity Attributable to Parent	$46,200	$42,159	$27,130	$20,670
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	250,000,000	250,000,000	250,000,000	250,000,000
Common Stock, Shares, Issued	13,317,000	17,536,000	656,000	673,000

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-23,516	$-21,819	$-19,472	$-15,724
Net Cash Provided by (Used in) Operating Activities	$-18,858	$-16,838	$-15,568	$-14,622
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-935	$-1,866	$1,311	$797
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$3,620	$1,754	$3,065	$2,725
Share-based Payment Arrangement, Noncash Expense	$5,196	$4,141	$3,420	$2,189
Proceeds from Sale, Maturity and Collection of Investments	$48,685	$56,939	$61,879	$84,297
Depreciation, Depletion and Amortization, Nonproduction	$220	$189	$136	$127
Payments to Acquire Investments	$56,520	$55,567	$46,018	$70,027
Operating Lease, Right-of-Use Asset, Amortization Expense	$326	$339	$353	$360
Payments to Acquire Property, Plant, and Equipment	$33	$37	$5	$5
Unrealized Gain (Loss) on Investments	$468	$-22	$-391	$-183
Net Cash Provided by (Used in) Investing Activities	$-7,868	$1,335	$15,856	$14,270
Proceeds from Other Equity	—	—	$13,591	—
Proceeds from Issuance of Common Stock	$25,800	—	$782	$782
Proceeds from Warrant Exercises	—	—	$241	$241
Proceeds from Stock Options Exercised	—	$46	$46	$46
Net Cash Provided by (Used in) Financing Activities	$25,791	$13,637	$1,023	$1,023
Increase (Decrease) in Prepaid Expense and Other Assets	$119	$70	$33	$134
Increase (Decrease) in Accounts Payable and Accrued Liabilities	—	$698	$1	$-1,153
IncreaseDecreaseInOperatingLeaseLiability	$-314	$-338	$-364	$-377

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("NVNO","financials")

Full statements spill as a table. For one cell: =jivedata("NVNO","Revenue") or =jivedata("NVNO","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.